search
Back to results

Clinical Trial Treatment in Lupus Nephritis (Csa-LES)

Primary Purpose

Lupus Nephritis

Status
Withdrawn
Phase
Phase 3
Locations
Spain
Study Type
Interventional
Intervention
cyclosporine +mycophenolic acid+prednison
Mycophenolic Acid + prednison
Sponsored by
Hospital Universitario Fundación Alcorcón
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lupus Nephritis focused on measuring Lupus nephritis, Therapy, Cyclosporin, Mycophenolic acid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18 years old
  • Patients diagnosed SLE with renal type III-IV-V confirmed by renal biopsy done in the last 6 months
  • Proteinuria > 2 g/24 hours and hematuria (> 5 h / field)
  • MDRD4 eGFR > 60 ml/min/1.73m2
  • Participant is willing and able to give informed consent for participation in the study

Exclusion Criteria:

  • Central nervous system LES involvement or any other vital organ
  • Active infection
  • Use of mycophenolic acid, mycophenolate mofetil, cyclosporine or tacrolimus in the last 6 months
  • No adherence
  • Women of childbearing age not using appropriate contraceptive methods.
  • Positive pregnancy test
  • Anasarca
  • Malignancy or cancer history (except basal cell skin carcinomas)
  • Patient participating in another study with an investigational drug or have participated within 28 days prior to entry into this study

Sites / Locations

  • Hospital Universitario Fundación Alcorcón

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

cyclosporine+mycophenolic acid+prednison

mycophenolic acid + prednison

Arm Description

Triple therapy

Mycophenolic acid+prednison 106 weeks

Outcomes

Primary Outcome Measures

the number of complete remissions, between the triple therapy with cyclosporine-prednisone-mycophenolic acid and conventional therapy with mycophenolic acid-prednisone as induction therapy in patients with lupus nephritis type III-IV-V
Complete remission: Proteinuria < 0.3 g/24h Albumin normal eGFR > 60 mL/min/1.73 m2

Secondary Outcome Measures

the number of partial and complete remissions, between triple therapy with prednisone, cyclosporine, mycophenolic acid and prednisone-mycophenolic acid.
Partial remission: Proteinuria 0.3-3.5 g/24 hours, with a decrease > 50% over basal, stable renal function and albumin normal
the number of patients with adverse effects
the rate (%) of decline of proteinuria in two groups
the decrease in GFR (ml/min/1.73m2) in both groups

Full Information

First Posted
February 18, 2011
Last Updated
February 26, 2015
Sponsor
Hospital Universitario Fundación Alcorcón
Collaborators
Hospital Universitario 12 de Octubre, Hospital General Universitario Gregorio Marañon, Hospital Universitario Ramon y Cajal, Hospital Infanta Sofia, Hospital Universitario Infanta Leonor, Hospital Universitario Reina Sofia de Cordoba, Hospital Regional Universitario Carlos Haya, Hospital Universitario Virgen de la Victoria, University Hospital of the Nuestra Señora de Candelaria, Hospital Universitario de Guadalajara. Spain, Hospital San Pedro de Alcantara, Hospital Juan Canalejo
search

1. Study Identification

Unique Protocol Identification Number
NCT01299922
Brief Title
Clinical Trial Treatment in Lupus Nephritis
Acronym
Csa-LES
Official Title
Phase III, Open, Randomized, Parallel-group Clinical Trial, to Evaluate the Efficacy and Safety of Treatment With Prednisone, Cyclosporine, Mycophenolic Acid Versus Prednisone and Mycophenolic Acid in Lupus Nephritis Type III-IV-V.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Withdrawn
Why Stopped
IT was impossible to find patients
Study Start Date
February 2011 (undefined)
Primary Completion Date
March 2014 (Anticipated)
Study Completion Date
October 2014 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Hospital Universitario Fundación Alcorcón
Collaborators
Hospital Universitario 12 de Octubre, Hospital General Universitario Gregorio Marañon, Hospital Universitario Ramon y Cajal, Hospital Infanta Sofia, Hospital Universitario Infanta Leonor, Hospital Universitario Reina Sofia de Cordoba, Hospital Regional Universitario Carlos Haya, Hospital Universitario Virgen de la Victoria, University Hospital of the Nuestra Señora de Candelaria, Hospital Universitario de Guadalajara. Spain, Hospital San Pedro de Alcantara, Hospital Juan Canalejo

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The treatment of lupus nephritis with cyclophosphamide and steroids changed the prognosis of lupus nephritis in the early '80s. In recent years, alternative regimens have appeared in both the induction and maintenance with similar results at least to those offered by the classic pattern and possibly with fewer side effects, especially for long term. The association of prednison and mycophenolate has created large expectations to that effect, and is part of first-line therapeutic arsenal of lupus nephritis type III, IV and V. Despite the significant advances that have led to these treatments, the likelihood of complete remission after six months remains, according to the series of 8-13% and partial remission do not exceed 60% in papers published. In the last year, two articles have been published supporting the use of triple therapy (prednisone, mycophenolate, cyclosporine) in poor prognosis of lupus nephritis with hopefully better results than those obtained previously. In this study we try to compare the effectiveness of triple therapy, the therapy is now considered standard (prednisone, mycophenolate) in patients with lupus nephritis type III-IV-V
Detailed Description
asd

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lupus Nephritis
Keywords
Lupus nephritis, Therapy, Cyclosporin, Mycophenolic acid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cyclosporine+mycophenolic acid+prednison
Arm Type
Experimental
Arm Description
Triple therapy
Arm Title
mycophenolic acid + prednison
Arm Type
Active Comparator
Arm Description
Mycophenolic acid+prednison 106 weeks
Intervention Type
Drug
Intervention Name(s)
cyclosporine +mycophenolic acid+prednison
Other Intervention Name(s)
Triple therapy
Intervention Description
Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
Intervention Type
Drug
Intervention Name(s)
Mycophenolic Acid + prednison
Other Intervention Name(s)
Conventional therapy
Intervention Description
Mycophenolic Acid + prednison for 106 weeks
Primary Outcome Measure Information:
Title
the number of complete remissions, between the triple therapy with cyclosporine-prednisone-mycophenolic acid and conventional therapy with mycophenolic acid-prednisone as induction therapy in patients with lupus nephritis type III-IV-V
Description
Complete remission: Proteinuria < 0.3 g/24h Albumin normal eGFR > 60 mL/min/1.73 m2
Time Frame
36 months
Secondary Outcome Measure Information:
Title
the number of partial and complete remissions, between triple therapy with prednisone, cyclosporine, mycophenolic acid and prednisone-mycophenolic acid.
Description
Partial remission: Proteinuria 0.3-3.5 g/24 hours, with a decrease > 50% over basal, stable renal function and albumin normal
Time Frame
36 months
Title
the number of patients with adverse effects
Time Frame
36 months
Title
the rate (%) of decline of proteinuria in two groups
Time Frame
36 months
Title
the decrease in GFR (ml/min/1.73m2) in both groups
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years old Patients diagnosed SLE with renal type III-IV-V confirmed by renal biopsy done in the last 6 months Proteinuria > 2 g/24 hours and hematuria (> 5 h / field) MDRD4 eGFR > 60 ml/min/1.73m2 Participant is willing and able to give informed consent for participation in the study Exclusion Criteria: Central nervous system LES involvement or any other vital organ Active infection Use of mycophenolic acid, mycophenolate mofetil, cyclosporine or tacrolimus in the last 6 months No adherence Women of childbearing age not using appropriate contraceptive methods. Positive pregnancy test Anasarca Malignancy or cancer history (except basal cell skin carcinomas) Patient participating in another study with an investigational drug or have participated within 28 days prior to entry into this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernandez Juarez Gema, MD Ph
Organizational Affiliation
Hospital Universitario Fundación Alcorcón
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Praga Terente Manuel, MD Ph
Organizational Affiliation
Hospital Universitario Doce de Octubre
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital Universitario Fundación Alcorcón
City
Alcorcon
State/Province
Madrid
ZIP/Postal Code
28922
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Clinical Trial Treatment in Lupus Nephritis

We'll reach out to this number within 24 hrs